New vaccine aims to wake up immune system against hepatitis b
NCT ID NCT07204236
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new vaccine called TVAX-008 in 20 adults with chronic hepatitis B who have very low levels of the virus. The goal is to see if the vaccine can safely boost the body's immune response, potentially helping control the infection. Participants will be monitored for changes in hepatitis B antibodies and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TVAX-008 injection
- What this could lead to
- If it works, this could point toward a way to help the immune system control chronic hepatitis B without lifelong medication.
- What could go wrong
- This is a very early, small trial (20 people) focused on safety and immune response. It may not lead to a treatment, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shandong Province Public Health Clinical Center
Jinan, Shandong, 250000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can a new injection tame chronic hepatitis b?
- Double liver trouble: does having both hepatitis b and fatty liver speed up disease?
- A second punch against hepatitis b: interferon after RNA drugs may clear the virus
- Could common hepatitis b drugs damage kidneys? a study digs into the data
- Can fatty liver and hepatitis b together harm kidneys? a study digs into the data